Results 121 to 130 of about 895 (134)

Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections

Seminars in Ophthalmology, 2020
Ahmad Mansour, Imoro Zeba Braimah
exaly  

Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular Degeneration (ZEBRA): A Prospective, Randomized Trial

Seminars in Ophthalmology, 2021
Haley D'Souza, Kapil G Kapoor
exaly  

Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor

Acta Ophthalmologica, 2020
Michel Eid Farah, Ahmad Mansour, Jay Chhablani   +2 more
exaly  

Use of Ziv Aflibercept in Different Retinal Diseases

Case Medical Research, 2020
openaire   +1 more source

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA

Medical Oncology, 2017
Mei Sheng Duh, JASMINA Ivanova, Francis Vekeman   +2 more
exaly  

One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema

Ophthalmology Retina, 2018
Masoud Soheilian, Mehdi Yaseri, Mohammad Hossein Jabbarpoor Bonyadi   +2 more
exaly  

Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial

Ophthalmology Retina, 2017
Masoud Soheilian, Ramin Nourinia, Mehdi Yaseri   +2 more
exaly  

Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model

Experimental Eye Research, 2018
Ariel Gore, Tamar Kádár, Liat Cohen
exaly  

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

British Journal of Cancer, 2013
J R Rigas, A A Adjei
exaly  

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

Cancer, 2018
, David Mcdermott, Ahmad Tarhini
exaly